High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia

  • Authors:
    • Maria Persson
    • Sophia Brismar Wendel
    • Linda Ljungblad
    • Bo Johansson
    • Elisabete Weiderpass
    • Sonia Andersson
  • View Affiliations

  • Published online on: April 3, 2012     https://doi.org/10.3892/or.2012.1755
  • Pages: 346-352
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to assess the use of human papillomavirus (HPV) E6/E7 mRNA testing in the follow-up of women treated for cervical intraepithelial neoplasia (CIN) by conization and to compare the prognostic value of HPV E6/E7 mRNA to HPV L1 DNA and cytology. One hundred and forty-three women underwent cytological/histological testing, HPV DNA genotyping by Linear Array, and HPV E6/E7 mRNA testing by APTIMA HPV assay during follow-up after surgical treatment for histologically verified CIN. High-grade residual/recurrent disease (CIN2+/HSIL+) was identified in 7 (4.9%) women, and low-grade disease (CIN1/LSIL) in 25 (17.5%). At the inclusion visit 33 (23%) women were HPV DNA-positive; 13 (9.0%) were HPV E6/E7 mRNA-positive. HPV E6/E7 mRNA did not identify three women with high-grade disease. Presence of high-risk HPV DNA at the inclusion visit predicted 100% (95% CI 64.6-100) of high-grade residual/recurrent disease, with a specificity of 80.9% (95% CI 73.5-86.6); cytology had a sensitivity of 85.7%, and a specificity of 87.5%. HPV E6/E7 mRNA testing was a poor predictor of treatment failure, with a sensitivity of 57.1% (95% CI 25.0-84.2), but high specificity (93.4%; 95% CI 87.9-96.5). Detection of high-risk HPV DNA after treatment by conization identified 100% of women with residual/recurrent high-grade disease, whereas HPV E6/E7 mRNA testing was a poor predictor of treatment failure. This study suggests that a negative HPV mRNA result cannot exclude the risk of malignant progression, and that HPV E6/E7 mRNA testing by APTIMA HPV assay is not useful in the follow-up of women treated for CIN.

Related Articles

Journal Cover

July 2012
Volume 28 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Persson M, Brismar Wendel S, Ljungblad L, Johansson B, Weiderpass E and Andersson S: High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia. Oncol Rep 28: 346-352, 2012
APA
Persson, M., Brismar Wendel, S., Ljungblad, L., Johansson, B., Weiderpass, E., & Andersson, S. (2012). High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia. Oncology Reports, 28, 346-352. https://doi.org/10.3892/or.2012.1755
MLA
Persson, M., Brismar Wendel, S., Ljungblad, L., Johansson, B., Weiderpass, E., Andersson, S."High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia". Oncology Reports 28.1 (2012): 346-352.
Chicago
Persson, M., Brismar Wendel, S., Ljungblad, L., Johansson, B., Weiderpass, E., Andersson, S."High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia". Oncology Reports 28, no. 1 (2012): 346-352. https://doi.org/10.3892/or.2012.1755